Biovail sues Anchen and Abrika over Wellbutrin XL

On Dec. 22, 2004, Biovail Corp. stated it has filed suit against Anchen Pharmaceuticals in California and Abrika Pharmaceuticals in Florida after they sought approval through an ANDA under the Hatch-Waxman Act to market a generic version of Biovail's Wellbutrin XL anti-depression drug.

Biovail said it filed the suits on behalf of itself and SmithKline Beecham Corp.